Revance Partnerships

Revance has strategically identified unique partnerships to reinforce our product pipeline 


In the first quarter of 2020, Revance entered into a distribution agreement with TEOXANE SA making Revance the exclusive commercialization partner of the company’s innovative RHA® Collection – resilient hyaluronic acid. Under the distribution agreement, Revance gained immediate and exclusive rights to commercialize the RHA® Collection of dermal fillers in the U.S., starting with the FDA-approved RHA® 2, RHA® 3, and RHA® 4 products, which include lidocaine. The agreement also includes a fourth product, RHA® Redensity™, which received FDA approval in 2021, and includes an ongoing collaboration with TEOXANE SA for a robust pipeline of additional indications and next-generation dermal filler technologies.

Biosimilar Partnership

In partnership with Viatris Inc. (formerly known as Mylan N.V.), Revance is developing a biosimilar to BOTOX®, which would allow Revance to compete in the existing short-acting neuromodulator marketplace, while focusing commercial efforts on creating a new, longer-acting neuromodulator category.

BOTOX® is a registered trademark of Allergan, Inc 

China Market License

We entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., (Fosun Pharma Industrial), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma), providing Fosun Pharma Industrial with the exclusive rights to develop and commercialize daxibotulinumtoxinA-lanm injection in mainland China, Hong Kong and Macau (the Territory). In the second quarter of 2021 Fosun Pharma initiated Phase 3 trials of daxibotulinumtoxinA-Ianm in China for the treatment of glabellar lines and cervical dystonia.


If you are interested in pursuing a corporate partnership please contact us by filling out the form below: